Lenvima 4 mg Capsule contains lenvatinib, a targeted anti-cancer medicine used for thyroid cancer, liver cancer, kidney cancer, and endometrial cancer. It works by blocking tumor growth pathways and reducing blood supply to cancer cells. Used under specialist oncology supervision.
Lenvima is the brand name for lenvatinib, an oral targeted therapy that belongs to a class of medicines known as multi-kinase inhibitors.
Cancer cells do not grow on their own.
They depend on signals that tell them when to divide and blood vessels that supply oxygen and nutrients. Lenvatinib disrupts both processes simultaneously.
That is why oncologists often use Lenvima when the goal is not simply to attack cancer cells directly, but to interfere with the biological systems tumors rely on to survive.
Today, Lenvima is approved in multiple countries for several difficult-to-treat cancers and has become an important treatment option in modern oncology.
Chemotherapy generally attacks rapidly dividing cells.
Lenvatinib takes a different approach.
It targets specific proteins involved in tumor growth and blood vessel formation, including VEGF receptors, FGF receptors, PDGF receptors, RET, and KIT signaling pathways.
By blocking these pathways, Lenvima may:
This targeted approach is one reason Lenvima has become a standard treatment option in several advanced cancers.
Lenvatinib is commonly prescribed for:
Treatment decisions depend on cancer type, disease stage, previous therapies, and overall patient health.
| Condition | Clinical Use |
|---|---|
| Differentiated Thyroid Cancer | Disease progression control |
| Hepatocellular Carcinoma (HCC) | Advanced liver cancer treatment |
| Renal Cell Carcinoma (RCC) | Kidney cancer therapy |
| Endometrial Cancer | Advanced or recurrent disease treatment |
| Advanced Solid Tumors | Specialist-directed use |
Cancer treatment is increasingly moving away from one-size-fits-all chemotherapy.
Targeted therapies such as lenvatinib allow specialists to attack specific biological pathways that drive tumor growth.
For patients with advanced thyroid cancer, liver cancer, or kidney cancer, slowing disease progression can be just as important as shrinking tumors.
That is where Lenvima has demonstrated its value.
Its role is not to cure every cancer. Its role is to help control cancers that rely on angiogenesis and growth signaling pathways to spread.
| Strength | Common Use |
|---|---|
| 4 mg | Dose adjustment and individualized regimens |
| 10 mg | Standard oncology dosing component |
| Combination Dosing | Multiple capsules used to achieve prescribed daily dose |
The total daily dose varies significantly depending on cancer type, body weight, treatment protocol, liver function, and physician recommendations.
| Attribute | Details |
|---|---|
| Generic Name | Lenvatinib |
| Brand Name | Lenvima® |
| Strength | 4 mg |
| Dosage Form | Capsule |
| Drug Class | Multi-Kinase Inhibitor |
| Route | Oral |
| Used For | Thyroid Cancer, Liver Cancer, Kidney Cancer, Endometrial Cancer |
No. Lenvima is a targeted therapy, not traditional chemotherapy. It works by blocking specific proteins involved in tumor growth and blood vessel formation.
Lenvima is commonly used for thyroid cancer, liver cancer, kidney cancer, and endometrial cancer under specialist supervision.
Treatment duration varies depending on response, side effects, disease progression, and oncology protocols.
In some patients, lenvatinib may reduce tumor size or slow tumor progression. Individual responses vary.
Yes. In certain cancers, lenvatinib may be combined with immunotherapy agents such as pembrolizumab under specialist guidance.
No. Lenvima is designed to help control cancer progression and improve treatment outcomes, but it is not considered a universal cure.
Answer: Yes. International shipping is available to many countries, subject to local import regulations and product availability.
Answer: Depending on stock availability, original branded Lenvima® manufactured by Eisai may be supplied.
Answer: Products are supplied in manufacturer-sealed pharmaceutical packaging and packed securely for international delivery.
Answer: Verify manufacturer information, batch number, expiry date, and original packaging upon receipt.
| Attribute | Details |
|---|---|
| Generic Name | Lenvatinib |
| Brand Name | Lenvima® |
| Strength | 4 mg |
| Dosage Form | Capsule |
| Administration | Oral |
| Drug Category | Targeted Cancer Therapy |
| Therapeutic Area | Oncology |
Orders ship from our India Head Office within 1–2 business days of confirmation. We include full customs documentation — HS codes, certificates of origin, and pharmaceutical export permits.
Estimated delivery: 3–7 business days to UK. 7–10 business days to UAE, Saudi Arabia and Gulf countries. 10–15 days for USA and Asian countries.
All packages arrive in plain, unmarked brown boxes. No pharmacy name or medication details on the outside.
★★★★★
Got custom deal after talking to hitubhai. Thanks milanmedicals.com for fast delivery and making tablets available at good price